Proprietary instrumentation and consumables for high throughput and ultra-high throughput screening for drug discovery. Bay City Capital sold its position in LJL in February 2000, and the company was subsequently acquired by Molecular Devices (NASDAQ:MDCC).
LJL Biosystems
